Xiaolin Liu (Co-founder, Chairman & CEO)

As Chairman and CEO of Biotheus, Xiaolin has over 20 years of experience in antibody discovery and development. Previously, Xiaolin served in R&D roles at Abbott, Bristol-Myers Squibb and Adimab. In 2012, Xiaolin was appointed as Vice President of R&D at Innovent Biologics where he led an R&D team of more than 100 scientists, and created a product development pipeline of more than 20 novel antibody-based assets. As the project leader, he successfully oversaw the discvoery, development and and launch of Tyvyt (sintilimab) on the Chinese market.

所属分类

Back To List

产品描述

[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[产品参数, 参数]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]

As Chairman and CEO of Biotheus, Xiaolin has over 20 years of experience in antibody discovery and development. Previously, Xiaolin served in R&D roles at Abbott, Bristol-Myers Squibb and Adimab. In 2012, Xiaolin was appointed as Vice President of R&D at Innovent Biologics where he led an R&D team of more than 100 scientists, and created a product development pipeline of more than 20 novel antibody-based assets. As the project leader, he successfully oversaw the discvoery, development and and launch of Tyvyt (sintilimab) on the Chinese market.

关键词:

the

and

of

than

as

more

r&d

antibody

in

扫二维码用手机看

Last

None